DPCO Pharma Pricing & Cost Records

Drug Price Control Order (DPCO), 2013 — issued under the Essential Commodities Act, 1955: brings formulations listed in the National List of Essential Medicines (NLEM) under statutory price control, administered by the National Pharmaceutical Pricing Authority (NPPA), the regulatory body responsible for fixing and revising ceiling prices of scheduled (NLEM) drugs and monitoring prices of non-scheduled formulations. Manufacturers of scheduled formulations must sell at or below the NPPA-notified ceiling price and are required to file periodic price, production and sales returns with NPPA under the DPCO's prescribed reporting forms; non-compliance can attract recovery of overcharged amounts with interest under the Essential Commodities Act framework. Ceiling prices for scheduled formulations are revised with reference to movements in the Wholesale Price Index (WPI), while non-scheduled formulations are permitted an annual price increase capped with reference to WPI movement, subject to NPPA monitoring — the current WPI-linked percentage cap and the current NLEM list should be verified against the live nppa.gov.in notification before being quoted to a client, as both are revised periodically. Advisory and cost-accounting support under this service covers preparing the cost data, DPCO return filings, and price-fixation representations that NPPA requires from manufacturers and marketers of NLEM-scheduled formulations.

DPCO compliance governs the pricing of scheduled pharmaceutical formulations in India. The Drugs (Prices Control) Order 2013 — made under Section 3 of the Essential Commodities Act 1955 — empowers the National Pharmaceutical Pricing Authority to fix ceiling prices for scheduled medicines and to regulate the prices of non-scheduled formulations. Manufacturers of scheduled formulations must sell at or below the ceiling price, and the Order requires the maintenance of cost data and records that demonstrate how the prices were derived (VERIFY: the specific clauses of DPCO 2013 governing ceiling price fixation and cost records).

The pricing is a statutory ceiling, not a marketing decision. For a scheduled medicine, the ceiling price is derived from the market price data of the formulation's pack sizes and strengths, and the manufacturer's price cannot exceed it. For non-scheduled formulations, the Order regulates the annual price increase to protect consumers from disproportionate hikes. Compliance means pricing the product correctly, maintaining the cost and price records, and responding to the NPPA's monitoring — including the monthly price lists and the audit of price data.

The cost of non-compliance is direct and enforced. The NPPA has the power to recover overcharged amounts and to impose penalties under the DPCO and the Essential Commodities Act 1955 (VERIFY: the penalty provisions applicable to DPCO violations). An overpriced scheduled medicine also draws the regulator's attention in the middle of the market the company depends on.

This service is for pharmaceutical manufacturers and importers with scheduled and non-scheduled formulations. We map your portfolio against the DPCO 2013 schedules, compute the ceiling price position, set up the cost records the Order requires, manage the NPPA's monitoring and price lists, and support you through price revision and penalty proceedings.